| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_da54f7ebbd2d9d8a82f92aca4d1b4e48 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-19 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate |
1997-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f87e701ec9d6bb1efca0cb0ef44af109
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_52ae64f5217645af5c2e18e407d9aea0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a6d5048d812c28e395f83ff43ec371f |
| publicationDate |
2001-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BG-63276-B1 |
| titleOfInvention |
METHOD FOR MANUFACTURING A MODIFIED PALIDIPINE INHIBITOR OF COLOGGENED THROMBOCITATION |
| abstract |
The method finds application for the production of recombinant protein Asr-palidipine, which suppresses collagen-induced platelet accumulation in mammals and cancer with metastatic tumor cells. Asp-palidipine includes a protein (palidipine) selected from the group of palidipine proteins, and an amino acid (aspartic) that is linked via a peptide bond to the N-terminal end of palidipine. The method consists of the following steps: a) transferring at least one bacterium with a suitable vector comprising DNA or cDNA encoding the recombinant Asp-palidipine, a suitable signal peptide sequence that cleaves so that the aspartic acid is +1 at the the amino acid sequence as seen from the position of palidipine and a suitable promoter; b) extraction of a preprotein comprising the ASp-palidipine and the signal sequence; c) transfer of Asp-palidipine from the cytoplasm of bacteria to the periplasm and cleavage of the preprotein by at least one protease during the transfer producing Asp-palidipine; d) isolation of Asp-palidipine by extraction of the periplasm; and f) purification of Asp-palidipine. |
| priorityDate |
1994-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |